Management of Myasthenia Gravis with Antifungal Therapy

Introduction to Myasthenia Gravis Management

The American Academy of Neurology recommends avoiding fluoroquinolones in patients with myasthenia gravis due to potential exacerbation of symptoms, and this warning applies broadly to medications that can impair the neuromuscular junction, including fluconazole 1
Critical medications to avoid in myasthenia gravis include β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics, as they can worsen neuromuscular transmission 1, 2

Approximately 50-80% of patients with myasthenia gravis can progress from ocular to generalized disease, and medication-induced exacerbations can trigger myasthenic crisis requiring intubation (MGFA Class V), with a significant risk of respiratory failure 3, 4
The risk of respiratory failure makes medication review an essential safety measure in all myasthenia gravis patients, with a focus on avoiding medications that can exacerbate symptoms 3

For systemic candidiasis, Amphotericin B deoxycholate (1 mg/kg IV daily) is recommended for initial treatment, and echinocandins (caspofungin, micafungin, anidulafungin) are safer alternatives 5
For less severe fungal infections, itraconazole may be considered with caution, though azole interactions with immunosuppressive medications used in myasthenia gravis must be carefully evaluated, and amphotericin B formulations remain the safest option when systemic antifungal therapy is required 2, 4, 5

Any patient with myasthenia gravis requiring antifungal therapy must have daily neurologic assessment for worsening weakness, frequent pulmonary function testing, ICU-level monitoring capability if moderate to severe disease, and immediate access to mechanical ventilation if respiratory compromise develops 3, 1, 4

The Infectious Diseases Society of America recommends echinocandins (caspofungin, micafungin, anidulafungin) as initial therapy for invasive candidiasis in myasthenia gravis patients, with dosing of caspofungin 70 mg loading dose then 50 mg daily, anidulafungin 200 mg loading then 100 mg daily, or micafungin 100 mg daily 6, 7
For prophylaxis in high-risk settings, the International Journal of Infectious Diseases suggests considering echinocandin prophylaxis instead of fluconazole 8
The Blood Cancer Journal recommends deviation from standard fluconazole prophylaxis in myasthenia gravis patients due to neuromuscular risks 9, 10
For coccidioidal meningitis, the Clinical Infectious Diseases journal suggests consultation with both infectious disease and neurology specialists to weigh the risks of untreated infection against neuromuscular exacerbation, and considering alternative treatments to fluconazole 11